YAP (Yes-associated protein) regulates cell growth, tissue homeostasis, and organ size as a transcription co-activator in the Hippo tumor suppressor pathway. The kinase Lats inhibits YAP by phosphorylating it, causing it to localize to the cytoplasm and be degraded by proteasomes. By attaching to transcription factors from the TEAD family, YAP stimulates the expression of genes.
YAP has a complicated role in human cancer that may vary depending on the cell type. For instance, by inducing apoptosis in response to DNA damage, YAP may act as a tumor suppressor in some cell types, such as hematological cancers.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69177 | IAG933 | 2714434-21-4 | IAG933 (YAP-TEAD-IN-3; compound 155) is a YAP/TAZ-TEAD inhibitor. |
|
V69175 | IK-930 | 2563892-44-2 | IK-930 (compound I-32) is a potent orally bioactive TEAD inhibitor (antagonist) with EC50 <0.1 µM. |
|
V117485 | LATS-IN-2 | 2248728-49-4 | LATS-IN-2 is a potent LATS inhibitor. |
|
V118692 | LATS1/2-IN-1 | 3024011-99-9 | LATS1/2-IN-1 is a highly effective and selective inhibitor of LATS1 and LATS2. |
|
V79966 | LM-41 | 2996821-30-6 | LM-41 is a Flufenamic acid-derived TEAD inhibitor that strongly reduces the expression of CTGF, Cyr61, Axl, and NF2. |
|
V139223 | M3686 | 2738550-24-6 | M3686 is a potent and selective TEAD1 inhibitor with an IC50 value of 51 nM. |
|
V139274 | MACTIDE-V | MACTIDE-V is an orally active selective peptide-drug conjugate that targets CD206. | |
|
V79664 | mCMY020 | mCMY020 is a TEAD covalent inhibitor. | |
|
V94432 | MSC-1254 | MSC-1254 is a reversible, selective and covalent TEAD1 inhibitor. | |
|
V94443 | MSC-5046 | MSC-5046 is a selective TEAD1 inhibitor. | |
|
V78452 | MY-1076 | 3008262-76-5 | MY-1076 is an inhibitor (blocker/antagonist) of YAP. |
|
V140537 | MY-1576 | MY-1576 is a FAK inhibitor with an IC50 value of 8 nM. | |
|
V2270 | MYF-01-37 | 2416417-65-5 | MYF-01-37 is a novel, potent and covalent TEAD inhibitor with anticancer activity. |
|
V88142 | NIBR-LTSi | NIBR-LTSi is a selective LATS kinase inhibitor that activates YAP signaling. | |
|
V141835 | OICR19451 | 2803349-61-1 | OICR19451 is an orally effective dual kinase inhibitor that inhibits NUAK1/NUAK2 and MARK2/MARK3 kinases. |
|
V111573 | OPN-9643 | 2866423-06-3 | OPN-9643 is a covalent inhibitor that targets the central palmitoyl binding pocket of TEAD, with an IC50 of 15 nM. |
|
V112507 | OPN-9652 | 2866423-35-8 | OPN-9652 is a potent oral covalent TEAD inhibitor (IC50 of 0.005 µM against MSTO-211H TEAD) that targets the central palmitate binding pocket of TEAD. |
|
V103683 | pan-TEAD-IN-1 | 3027484-09-6 | pan-TEAD-IN-1 (compound 3) is an orally available pan-TEAD inhibitor that inhibits the transcriptional upregulation of oncogenes (such as Ctgf and Cyr61) in the Hippo signaling pathway by targeting the palmitoylation site of TEAD and interfering with its interaction with the coactivators YAP/TAZ. |
|
V109111 | PROTAC TEAD degrader-2 | 2918762-17-9 | PROTAC TEAD Degrader-2 (Compound 31) is a highly efficient TEAD1 PROTAC degrader with a DC50 value of 0.6 nM. |
|
V143405 | PROTAC TEAD/IAP degrader-1 | PROTAC TEAD/IAP degrader-1 is a TEAD/IAP PROTAC degrading agent. |